46 results
424B5
IKT
Inhibikase Therapeutics Inc
22 May 24
Prospectus supplement for primary offering
8:55am
by physicians, patients, healthcare payors, and others in the medical community necessary for commercial success;
Even if we are able to commercialize any … product candidates, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform
424B5
24pyb6v
1 Feb 24
Prospectus supplement for primary offering
4:49pm
424B3
iqrnoxhikdhybn
4 Apr 23
Prospectus supplement
4:57pm
POS AM
m9kao4
31 Mar 23
Prospectus update (post-effective amendment)
4:11pm